PL2598142T3 - Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby - Google Patents

Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby

Info

Publication number
PL2598142T3
PL2598142T3 PL11720594T PL11720594T PL2598142T3 PL 2598142 T3 PL2598142 T3 PL 2598142T3 PL 11720594 T PL11720594 T PL 11720594T PL 11720594 T PL11720594 T PL 11720594T PL 2598142 T3 PL2598142 T3 PL 2598142T3
Authority
PL
Poland
Prior art keywords
treatment
diphenyl ether
ether compounds
liver disorders
disorders
Prior art date
Application number
PL11720594T
Other languages
English (en)
Polish (pl)
Inventor
Shridhar Narayanan
Jeyamurugan Mookkan
Jayanarayan Kulathingal
Surendran Narayanan
Gajendra Singh
Gopalan Balasubramanian
Original Assignee
Orchid Chemicals And Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals And Pharmaceuticals Ltd filed Critical Orchid Chemicals And Pharmaceuticals Ltd
Publication of PL2598142T3 publication Critical patent/PL2598142T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11720594T 2010-07-28 2011-03-28 Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby PL2598142T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2140CH2010 2010-07-28
IN525CH2011 2011-02-23
EP11720594.8A EP2598142B1 (en) 2010-07-28 2011-03-28 Diphenyl ether compounds for use in the treatment of liver disorders
PCT/IN2011/000210 WO2012014218A1 (en) 2010-07-28 2011-03-28 Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL2598142T3 true PL2598142T3 (pl) 2016-06-30

Family

ID=44247871

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11720594T PL2598142T3 (pl) 2010-07-28 2011-03-28 Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby

Country Status (11)

Country Link
US (1) US20140187594A1 (enExample)
EP (2) EP2987488A1 (enExample)
JP (1) JP5957452B2 (enExample)
CN (1) CN103108634B (enExample)
AU (1) AU2011284256B8 (enExample)
CA (1) CA2805245A1 (enExample)
ES (1) ES2565487T3 (enExample)
HU (1) HUE028725T2 (enExample)
PL (1) PL2598142T3 (enExample)
WO (1) WO2012014218A1 (enExample)
ZA (1) ZA201300822B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN113750089B (zh) * 2021-10-13 2023-09-19 南方医科大学南方医院 2-芳基-1,3二氢苯并咪唑衍生物在制备治疗慢性肝病的药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109175A (ja) * 1994-10-07 1996-04-30 Torii Yakuhin Kk チアゾリジン−２−オンエステル誘導体
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
US6794401B2 (en) 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
JP2008533122A (ja) * 2005-03-18 2008-08-21 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド 新規なチロシン誘導体
WO2006138475A2 (en) * 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
CA2696053A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
CL2008000670A1 (es) * 2007-03-07 2008-11-03 Janssen Pharmaceutica Nv Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
WO2009030968A1 (en) * 2007-09-05 2009-03-12 Orchid Research Laboratories Limited Mao a inhibitors with a diphenyl ether-substructure.
EP2214480B1 (en) * 2007-11-30 2013-03-27 The Regents of the University of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Also Published As

Publication number Publication date
ES2565487T3 (es) 2016-04-05
EP2987488A1 (en) 2016-02-24
JP2013532682A (ja) 2013-08-19
EP2598142B1 (en) 2015-12-16
HUE028725T2 (en) 2016-12-28
WO2012014218A1 (en) 2012-02-02
AU2011284256B8 (en) 2014-11-13
EP2598142A1 (en) 2013-06-05
ZA201300822B (en) 2014-04-30
CN103108634A (zh) 2013-05-15
CN103108634B (zh) 2015-08-12
CA2805245A1 (en) 2012-02-02
AU2011284256A1 (en) 2013-02-14
JP5957452B2 (ja) 2016-07-27
AU2011284256A8 (en) 2014-11-13
AU2011284256B2 (en) 2014-05-29
US20140187594A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
HRP20181185T1 (hr) Inhibitori ibat za liječenje bolesti jetre
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201403795B (en) Formulations for the treatment of diabetes
EP2683370A4 (en) THIOL-CONTAINING COMPOUNDS FOR REMOVING ELEMENTS OF WOVEN FABRICS AND FORMULATIONS THEREFOR
SI2605764T1 (sl) Sestavki za zdravljenje raka
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
PL2882724T3 (pl) Związki do zastosowania w leczeniu zaburzeń, które są łagodzone poprzez hamowanie HDAC
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
PL2598142T3 (pl) Związki eteru difenylowego do zastosowania w leczeniu zaburzeń wątroby
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
LT2460509T (lt) Kompozicija, skirta karpų gydymui
GB201016486D0 (en) Compounds for the use in treatment of plants
GB201019482D0 (en) Compounds for the treatment of metabolic disorders
GB201004740D0 (en) Compounds for the treatment of metabolic disorders
GB201004741D0 (en) Compounds for the treatment of metabolic disorders
GB201004742D0 (en) Compounds for the treatment of metabolic disorders
GB201004744D0 (en) Compounds for the treatment of metabolic disorders
GB201006163D0 (en) Compounds for the treatment of metabolic disorders
GB201006164D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
IL232294A0 (en) Preparations for the treatment of diabetes
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
IL223055A0 (en) Compositions for the treatment of gynaecological disorders